In 2022, around 1.4 million people in Australia were estimated to have some form of heart, stroke and vascular disease. This is an increase of around 170 thousand people from the previous National Health Survey conducted in 2018.

The CHAT study was a randomised control trial of telephone support for Chronic Heart Failure (CHF) patients at high risk of rehospitalisation. This project was funded by the NHMRC, Heart Foundation of Australia and the Medical Benefits Fund. The project implemented the first Australia-wide trial of telephone support for CHF patients. The aims of the study were to determine whether automated telephone support would improve quality of life and reduce death & hospital admission for rural and remote CHF patients, and to test this system of care as an exemplar of a novel chronic disease management strategy in areas remote from access to multi-disciplinary care. The automated telephone support comprised an interactive telecommunication software tool (Telewatch) with follow-up by trained cardiac nurses. Patients with a general practice (GP) diagnosis of heart failure were randomised to telephone support (217 patients) or usual care (188 patients) using a cluster design involving 136 GPs throughout Australia. Results showed that automated telephone support to rural & remote heart failure patients resulted in a 30% reduction in risk of all-cause death & hospitalisation.

In 2022, the most common long-term health condition reported by Australians were mental and behavioral conditions, representing 26.1 percent of the population. By comparison, diabetes and heart diseases affected around five percent of the population each. Mental health in Australia Around 27.6 percent of the Australian population suffered from depression or symptoms of depression in 2020 amidst the COVID pandemic. Despite so many Australians being affected by mental illness, many do not initially seek help or know where to look to find help. For those that do seek help, not for profit organizations like Beyond Blue, the Black Dog Institute, and Sane are available for Australians to receive information and support. For young people, Headspace is a government funded national youth support service. However, in a 2022 survey on where young people go for help, around 80 percent of young people indicated that they feel most comfortable speaking with their friends about important issues such as mental health.  Chronic illness as an underlying cause of death Diabetes was a considerable underlying cause of death in the Australian population in 2020. The rate has not changed significantly over the past 20 years compared to other prevalent causes of death, like cancer. Arthritis, hypertension, and asthma are among the most common chronic illnesses in Australia, but these illnesses alone are not usually significant contributors to a cause of death.

In Australia Ischemic Heart Disease Market, It has experienced significant growth in recent years due to the rising prevalence of cardiovascular diseases, changing lifestyle factors, and advancements in diagnostic and therapeutic technologies.

IntroductionAdult male and female mortality declines in Japan have been slower than in most high-income countries since the early 1990s. This study compares Japan’s recent life expectancy trends with the more favourable trends in Australia, measures the contribution of age groups and causes of death to differences in these trends, and places the findings in the context of the countries’ risk factor transitions.MethodsThe study utilises data on deaths by age, sex and cause in Australia and Japan from 1950–2016 from the Global Burden of Disease Study. A decomposition method measures the contributions of various ages and causes to the male and female life expectancy gap and changes over four distinct phases during this period. Mortality differences by cohort are also assessed.FindingsJapan’s two-year male life expectancy advantage over Australia in the 1980s closed in the following 20 years. The trend was driven by ages 45–64 and then 65–79 years, and the cohort born in the late 1940s. Over half of Australia’s gains were from declines in ischaemic heart disease (IHD) mortality, with lung cancer, chronic respiratory disease and self-harm also contributing substantially. Since 2011 the trend has reversed again, and in 2016 Japan had a slightly higher male life expectancy. The advantage in Japanese female life expectancy widened over the period to 2.3 years in 2016. The 2016 gap was mostly from differential mortality at ages 65 years and over from IHD, chronic respiratory disease and cancers.ConclusionsThe considerable gains in Australian male life expectancy from declining non-communicable disease mortality are attributable to a range of risk factors, including declining smoking prevalence due to strong public health interventions. A recent reversal in life expectancy trends could continue because Japan has greater scope for further falls in smoking and far lower levels of obesity. Japan’s substantial female life expectancy advantage however could diminish in future because it is primarily due to lower mortality at old ages.

Ischaemic heart disease was the leading cause of death for Australian males in 2023, with just over ten thousand deaths registered in that year. For Australian women, dementia and Alzheimer's disease were the leading cause of death, followed by Ischaemic heart disease.

The Australian cardiac surgery instruments market, valued at approximately $80 million in 2025, is projected to experience robust growth, driven by an aging population, increasing prevalence of cardiovascular diseases, technological advancements in minimally invasive surgical techniques, and rising demand for advanced cardiac devices. This expanding market presents significant opportunities for both established players like Medtronic, Boston Scientific, and Abbott Laboratories, and emerging companies focusing on innovative technologies. The segment encompassing diagnostic and monitoring devices, particularly electrocardiograms (ECGs) and remote cardiac monitoring systems, is anticipated to witness faster growth compared to therapeutic and surgical devices. This is attributed to increasing adoption of telehealth and remote patient monitoring, allowing for earlier diagnosis and improved patient outcomes. However, factors like high costs associated with advanced devices and procedures, along with stringent regulatory requirements, could act as potential restraints to market expansion. The market's growth trajectory will likely be influenced by government healthcare initiatives aimed at improving cardiovascular health and increasing access to advanced cardiac care. Further expansion can be expected through increased adoption of minimally invasive techniques that reduce recovery times and improve patient outcomes, driving demand for specialized instruments suited to these procedures. The forecast period of 2025-2033 anticipates a consistent Compound Annual Growth Rate (CAGR) of 7.66%, indicating a steady increase in market value. While specific regional data for Australia is absent, the national market will likely benefit from the broader global trends mentioned above, combined with Australia's robust healthcare infrastructure and relatively high per capita healthcare spending. Competitive intensity within the market remains high, with both multinational corporations and specialized companies vying for market share. The market's future growth will depend on a dynamic interplay between technological innovation, regulatory landscape, and healthcare policy developments. Continuous innovation in minimally invasive surgery and advanced diagnostic techniques will be crucial for sustaining the projected growth trajectory. Recent developments include: February 2024: Monash University led a transdisciplinary consortium to develop and commercialize a suite of revolutionary and life-changing implantable cardiac devices that, for the first time, would offer longer-term solutions for all types of debilitating heart failure.June 2022: Teleflex Incorporated, a leading global provider of medical technologies, launched its Arrow Pressure Injectable Midline Catheter in Australia. The addition of the pressure injectable catheter further enhances the Midline portfolio to meet the expanded needs of clinicians and is designed to improve patient safety. The new 20-cm Arrow Pressure Injectable Midline with brightly colored yellow hubs and labeling will help clinicians overcome catheter identification confusion, which can lead to infusion mistakes that can harm patients.. Key drivers for this market are: Increasing Burden of Cardiovascular Diseases, Increased Preference for Minimally Invasive Procedures and Technological Advancements in Cardiovascular Devices. Potential restraints include: Increasing Burden of Cardiovascular Diseases, Increased Preference for Minimally Invasive Procedures and Technological Advancements in Cardiovascular Devices. Notable trends are: Electrocardiogram (ECG) Segment is Expected to Witness Growth Over the Forecast Period.

BackgroundEngaging in chronically stressful behaviours has been hypothesised to increase the risk of experiencing cardiovascular disease (CVD). Providing unpaid care is known to be a stressful activity, but it is not clear whether this caregiving is associated with CVD. This study filled a gap in the existing literature by examining the association between providing unpaid care and incident cardiovascular disease among a nationally representative sample of Australian adults.Methods11,123 adult participants aged over 18 years from the Household Income and Labour Dynamics in Australia (HILDA) survey were followed for up to 14 years from baseline (2003) until 2017. Gender-stratified survival analysis models used self-reported caregiving and heart disease statuses as well as time-varying covariates, to assess the association between providing high-intensity or low-intensity unpaid care (to an elderly or disabled relative) and incident CVD in comparison with a non-caregiving control.ResultsAmong females, there was weak evidence that CVD was associated with high-intensity unpaid care (HR = 1.27, 95% CI = [0.83, 1.95]) and no evidence for low-intensity unpaid care (HR = 0.79, 95% CI = [0.50, 1.26]) in comparison with non-carers after adjusting for confounders. There was no association between caregiving and incident CVD for high-intensity (HR = 0.82, 95% CI = [0.47, 1.42]) or low-intensity (HR = 0.84, 95% CI = [0.55, 1.28]) caregiving males in the adjusted models.ConclusionsThese findings do not provide strong evidence to reject the null hypothesis that providing unpaid care does not increase risk of developing CVD in the Australian population. Given that these findings are somewhat inconsistent with the extant literature from other populations, further research is necessary, both in Australia and internationally, to build on the findings of this study and improve understanding of the nature of the association between caregiving and incident CVD.

Main objectiveThe aim of this study was to explore the perception of patients with cardiovascular disease towards oral health and the potential for cardiac care clinicians to promote oral health.MethodA needs assessment was undertaken with twelve patients with cardiovascular disease attending cardiac rehabilitation between 2015 and 2016, in three metropolitan hospitals in Sydney, Australia. These patients participated in face-to-face semi-structured interviews. Data was analysed using thematic analysis.ResultsResults suggested that while oral health was considered relevant there was high prevalence of poor oral health among participants, especially those from socioeconomic disadvantaged background. Awareness regarding the importance of oral health care its impact on cardiovascular outcomes was poor among participants. Oral health issues were rarely discussed in the cardiac setting. Main barriers deterring participants from seeking oral health care included lack of awareness, high cost of dental care and difficulties in accessing the public dental service. Findings also revealed that participants were interested in receiving further information about oral health and suggested various mediums for information delivery. The concept of cardiac care clinicians, especially nurses providing education, assessment and referrals to ongoing dental care was well received by participants who felt the post-acute period was the most appropriate time to receive oral health care advice. The issues of oral health training for non-dental clinicians and how to address existing barriers were highlighted by participants.Relevance to clinical practiceThe lack of oral health education being provided to patients with cardiovascular disease offers an opportunity to improve care and potentially, outcomes. In view of the evidence linking poor oral health with cardiovascular disease, cardiac care clinicians, especially nurses, should be appropriately trained to promote oral health in their practice. Affordable and accessible dental care services for people with cardiovascular disease should be considered and offered by health services in Australia.

In the 2022 financial year, around six million Australian adults suffered from hay fever and allergic rhinitis. A further 6.6 million Australian adults were estimated to suffer a mental or behavioral condition.

Utilising digital health technologies to aid individuals in managing chronic diseases offers a promising solution to overcome health service barriers such as access and affordability. However, their effectiveness depends on adoption and sustained use, influenced by user preferences.

This study quantifies the preferences of individuals with chronic heart disease for features of a mobile health app to self-navigate their disease condition.

We conducted an unlabelled online choice survey among adults over 18 with chronic heart disease living in Australia, recruited via an online survey platform. Four app attributes—ease of navigation, monitoring of blood pressure and heart rhythm, health education, and symptom diary maintenance—were systematically chosen through a multi-stage process. This process involved a literature review, stakeholder interviews, and expert panel discussions. Participants chose a preferred mobile app out of three alternatives, app A, app B, or neither. A D-optimal design was developed using Ngene software, informed by Bayesian priors derived from pilot survey data. Latent class model (LCM) analysis was conducted using Nlogit software. We also estimated attribute importance and anticipated adoption rates for three app versions.

Snapshot img

Cardiac Rehabilitation Market Size 2024-2028

The cardiac rehabilitation market size is forecast to increase by USD 1.97 billion at a CAGR of 6.59% between 2023 and 2028.

The market is witnessing significant growth due to the high prevalence of cardiovascular diseases. According to the World Health Organization, an estimated 17.9 million people died from cardiovascular diseases in 2016, representing 31% of all global deaths. This underscores the urgent need for effective cardiac rehabilitation programs to manage and reduce the burden of these conditions. Another key trend driving market growth is the increasing adoption of telerehabilitation. With advancements in technology, remote monitoring and virtual care are becoming increasingly popular in cardiac rehabilitation. Telerehabilitation offers several advantages, including reduced travel time and costs, increased patient convenience, and improved access to care in remote areas.
However, cost barriers remain a significant challenge for the market. The high cost of cardiac rehabilitation programs, including hospital fees, medications, and travel expenses, can be a major obstacle for many patients. Additionally, lack of insurance coverage and limited reimbursement policies further hinder the affordability of these programs. To capitalize on market opportunities and navigate these challenges effectively, companies should explore innovative pricing models, partnerships with insurance providers, and the integration of cost-effective telerehabilitation solutions.

What will be the Size of the Cardiac Rehabilitation Market during the forecast period?

Request Free Sample

The market continues to evolve, integrating advanced technologies and innovative approaches to improve patient outcomes and functional independence. machine learning algorithms and wearable technology enable personalized care plans, while patient engagement tools like mobile health apps and virtual reality enhance rehabilitation programs. Health information technology, including telemedicine platforms, patient portals, and Electronic Health Records, facilitate remote monitoring and data analytics. Heart failure rehabilitation programs incorporate stress management techniques, risk factor management, and artificial intelligence to optimize treatment plans. Functional capacity assessments using data from wearable technology and biofeedback systems inform exercise programs and nutritional counseling.
Cardiopulmonary rehabilitation programs employ home-based exercise equipment and remote monitoring to support functional independence and patient satisfaction. Augmented reality and virtual reality technologies offer immersive experiences for secondary prevention and myocardial infarction recovery. Artificial intelligence and data analytics play a crucial role in predicting and managing heart transplant patients' post-operative care. Psychological support, lifestyle modification, and personalized care plans are essential components of holistic rehabilitation programs. The ongoing integration of these technologies and approaches in cardiac rehabilitation programs underscores the dynamic nature of the market. Continuous innovation and adaptation to patient needs will remain key drivers of growth and success in this evolving landscape.

How is this Cardiac Rehabilitation Industry segmented?

The cardiac rehabilitation industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Rehab centers
  Hospitals
  Clinics
  Others


Type

  Phase I
  Phase II
  Phase III


Technology Specificity

  Wearable Devices
  Tele-Rehabilitation
  Mobile Apps


Application

  Coronary Artery Disease
  Heart Failure
  Post-Surgery Recovery


Geography

  North America

    US
    Mexico


  Europe

    France
    Germany
    Italy
    Spain
    UK


  Middle East and Africa

    UAE


  APAC

    Australia
    China
    India
    Japan
    South Korea


  South America

    Brazil


  Rest of World (ROW)

By End-user Insights

The rehab centers segment is estimated to witness significant growth during the forecast period.

Cardiac rehabilitation refers to specialized programs designed to help individuals recover from cardiac events, such as myocardial infarction or cardiac surgery. These programs aim to improve functional capacity, enhance quality of life, and reduce the risk of future cardiac events. The market encompasses various services, including inpatient and outpatient rehabilitation, home-based rehabilitation, and remote monitoring. Physical therapy and occupational therapy are essential components of cardiac rehabilitation, focusing on improving functional independence and enhancing exercise tolerance. Smoking cessation and nutritio

The descriptive statistics for clinical variables in the preexistent and acquired cardiac groups of women in South Australia during 2003 and 2013.

This data collection contains de-identified clinical health service utilisation data from Bendigo Health and the General Practitioners Practices associated with the Loddon Mallee Murray Medicare Local. The collection also includes associated population health data from the ABS, AIHW and the Municipal Health Plans. Health researchers have a major interest in how clinical data can be used to monitor population health and health care in rural and regional Australia through analysing a broad range of factors shown to impact the health of different populations. The Population Health data collection provides students, managers, clinicians and researchers the opportunity to use clinical data in the study of population health, including the analysis of health risk factors, disease trends and health care utilisation and outcomes.Temporal range (data time period):2004 to 2014Spatial coverage:Bendigo Latitude -36.758711200000010000, Bendigo Longitude 144.283745899999990000

This dataset, released February 2021, contains the statistics of premature mortality by various causes for people below 75 years, over the years 2014 to 2018. Causes for death include cancer (colorectal, lung, breast), diabetes, circulatory system diseases (ischaemic heart disease, cerebrovascular disease), respiratory system diseases (chronic obstructive pulmonary disease), and external causes (road traffic injuries, suicide and self-inflicted injuries) The data is by Local Government Area (LGA) 2016 geographic boundaries. For more information please see the data source notes on the data. Source: Data compiled by PHIDU from deaths data based on the 2014 to 2018 Cause of Death Unit Record Files supplied by the Australian Coordinating Registry and the Victorian Department of Justice, on behalf of the Registries of Births, Deaths and Marriages and the National Coronial Information System. The population is the ABS Estimated Resident Population (ERP) for Australia, 30 June 2014 to 30 June 2018. AURIN has spatially enabled the original data. Data that was not shown/not applicable/not published/not available for the specific area ('#', '..', '^', 'np, 'n.a.', 'n.y.a.' in original PHIDU data) was removed.It has been replaced by by Blank cells. For other keys and abbreviations refer to PHIDU Keys.

The number of potentially avoidable deaths and their cause at age 0 to 74 years with corresponding mortality rates/ratios with respective confidence intervals, 2010 - 2014. The specified causes of death are: cancers, colorectal cancer, breast cancer, circulatory system diseases, ischaemic heart disease, cerebrovascular disease, respiratory system diseases, chronic obstructive pulmonary disease, deaths from select external causes of mortality, suicide and self-inflicted injuries, other external causes of mortality, transport accidents. (all entries that were classified as not shown, not published or not applicable were assigned a null value; no data was provided for Maralinga Tjarutja LGA, in South Australia). The data is by LGA 2015 profile (based on the LGA 2011 geographic boundaries). For more information on statistics used please refer to the PHIDU website, available from: http://phidu.torrens.edu.au/. For information on the avoidable mortality concept please refer to the Australian and New Zealand Atlas of Avoidable Mortality, available from: http://phidu.torrens.edu.au/. Source: Data compiled by PHIDU from deaths data based on the 2010 to 2014 Cause of Death Unit Record Files supplied by the Australian Coordinating Registry and the Victorian Department of Justice, and ABS Estimated Resident Population (ERP), 30 June 2010 to 30 June 2014.

Data from a randomised controlled trial of thermal clothing vs usual care for heart failure patients in Brisbane, Australia. All data are in R format. Participants are linked by their "record_id"/"id" number.Data are:- Diary.RData, clothing diaries with CLO score- Loggers.RData, indoor temperature data- Trial.data.RData, main trial data collected at baseline, midwinter and the end of winter- ThermalClothingStudy_DataDictionary, data dictionary from REDCap databaseIf you use the data please cite the BMJ Open paper and acknowledge the funding from the Heart Foundation.

ICD-10 coded broad underlying causes of death in the Australian population as a whole, and in this study.

This dataset, released February 2021, contains the statistics of premature mortality by various causes for people below 75 years, over the years 2014 to 2018. Causes for death include cancer (colorectal, lung, breast), diabetes, circulatory system diseases (ischaemic heart disease, cerebrovascular disease), respiratory system diseases (chronic obstructive pulmonary disease), and external causes (road traffic injuries, suicide and self-inflicted injuries) The data is by Population Health Area (PHA) 2016 geographic boundaries based on the 2016 Australian Statistical Geography Standard (ASGS). Population Health Areas, developed by PHIDU, are comprised of a combination of whole SA2s and multiple (aggregates of) SA2s, where the SA2 is an area in the ABS structure. For more information please see the data source notes on the data. Source: Data compiled by PHIDU from deaths data based on the 2014 to 2018 Cause of Death Unit Record Files supplied by the Australian Coordinating Registry and the Victorian Department of Justice, on behalf of the Registries of Births, Deaths and Marriages and the National Coronial Information System. The population is the ABS Estimated Resident Population (ERP) for Australia, 30 June 2014 to 30 June 2018. AURIN has spatially enabled the original data. Data that was not shown/not applicable/not published/not available for the specific area ('#', '..', '^', 'np, 'n.a.', 'n.y.a.' in original PHIDU data) was removed.It has been replaced by by Blank cells. For other keys and abbreviations refer to PHIDU Keys.

The datasets generated and /or analysed during the current study are not publicly available due to participant identifying factors but are available from the corresponding author on reasonable written request.

Background: Rheumatic fever (RF) and rheumatic heart disease (RHD) cause considerable morbidity and mortality amongst Australian Aboriginal and Torres Strait Islander populations. Secondary antibiotic prophylaxis in the form of 4-weekly benzathine penicillin injections is the mainstay of control programs. Evidence suggests, however, that delivery rates of such prophylaxis are poor. Methods: This qualitative study used semi-structured interviews with patients, parents/care givers and health professionals, to explore the enablers of and barriers to the uptake of secondary prophylaxis. Data from participant interviews (with 11 patients/carers and 11 health practitioners) conducted in four far north Queensland sites were analyzed using the method of constant comparative analysis. Results: Deficits in registration and recall systems and pain attributed to injections were identified as barriers to secondary prophylaxis uptake. There were also varying perceptions regarding responsibility for ensuring injection delivery. Enablers of secondary prophylaxis uptake included positive patient-healthcare provider relationships, supporting patient autonomy, education of patients, care givers and healthcare providers, and community-based service delivery. Conclusion: The study findings provide insights that may facilitate enhancement of secondary prophylaxis delivery systems and thereby improve uptake of secondary prophylaxis for RF/RHD.